DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin Peanut in Toddlers - Seite 3

Late-Breaking Abstract (poster presentation):

“EPOPEX, Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Toddlers: 1-year Open-Label Extension to EPITOPE”

• Presenter: Matthew C. Greenhawt, MD, MSc, MBA, FACAAI, Children’s Hospital Colorado, Anschutz Medical Campus, Aurora, CO.
• Session:   Late-breaking Oral Abstracts - Session 1: Food Allergy
• Day: Saturday, November 11
• Time: 9:35 – 10:00 AM (PT)
• Location:   Exhibit Hall C – ePoster Area – LIVE Presentation Stage

“On behalf of the food allergy community, we are so pleased to see the results from the open-label extension to the EPITOPE study" said Eleanor Garrow-Holding, CEO, Food Allergy and Anaphylaxis Connection Team. “Patients and families are eagerly awaiting FDA-approved options that may be appropriate for their unique medical needs and lifestyle. Viaskin Peanut, if approved, has the potential to be an efficacious and well-tolerated treatment with a promising safety profile. We look forward to DBV’s continued regulatory progress and the initiation of the COMFORT Toddlers safety study to support a future BLA submission and FDA’s potential review of this innovative product.”

Investor Conference Call and Webcast
DBV management will host an investor conference call and webcast today, November 9^th, at 5:00pm EST, to discuss the EPOPEX data. This call is accessible via the below teleconferencing numbers and requesting the DBV Technologies call.

• United States: [phone]
• International: [phone]

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).